Scorpion Nabs $108m, Biopharma Veterans For Precision Oncology 2.0

Serial Entrepreneur Gary Glick Previously Founded IFM, Lycera, FirstWave

 
• By Mandy Jackson

The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.

Business, Technology, Internet and network concept. Young businessman working on a virtual screen of the future and sees the inscription: venture capital
Scorpion closed a $108m series A round to fund precision oncology drugs • Source: Shutterstock

More from Financing

More from Business